Canadian Drug Facility Cited for Contamination Risks By Sam | January 8, 2019 Contract drug manufacturer Jubilant HollisterStier drew a Form 483 after the FDA observed contamination risks at the firm’s Kirkland, Quebec facility. Source: Drug GMP Report Posted in Drug GMP Report